Table 1.

Potency, expressed as IC50 concentrations, for pyriplatin, cisplatin, and oxaliplatin on cancer cell proliferation in a 10-cell line panel after 24-hour incubation

Cell lineCancer typeIC50 (μmol/L)
PyriplatinCisplatinOxaliplatin
HOP-92Non–small cell lung171 ± 563.55 ± 3.22.70 ± 0.60
HOP-62Non–small cell lung190 ± 363.56 ± 1.46.86 ± 0.39
IGROV1Ovarian230 ± 335.64 ± 1.38.08 ± 2.9
COLO205Colorectal266 ± 5716.7 ± 7.22.84 ± 0.64
HCT-116Colorectal281 ± 504.22 ± 2.51.10 ± 0.28
OVCAR-3Ovarian328 ± 1285.10 ± 3.01.24 ± 0.30
MCF7Breast335 ± 10415.6 ± 6.41.70 ± 0.54
HCC-2998Colorectal381 ± 10311.8 ± 4.07.27 ± 2.3
MDA-435Breast/melanoma401 + 1565.81 + 4.012.7 + 5.6
HT29Colorectal443 + 25511.9 + 4.16.65 + 1.0

NOTE: Data are means ± SEM from 3 separate experiments, each conducted in triplicate.